Journal Article

DKFZ-2024-01039

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial.

Krilaviciute, A. (First author)DKFZ* ; Kaaks, R.DKFZ* ; Seibold, P.DKFZ* ; de Vrieze, M.DKFZ* ; Lakes, J. ; Radtke, J. P. ; Kuczyk, M. ; Harke, N. N. ; Debus, J.DKFZ* ; Fink, C.DKFZ* ; Herkommer, K. ; Gschwend, J. E. ; Meissner, V. H. ; Benner, A.DKFZ* ; Kristiansen, G. ; Hadaschik, B.DKFZ* ; Arsov, C. ; Schimmöller, L. ; Antoch, G. ; Giesel, F. L. ; Makowski, M. ; Wacker, F. ; Schlemmer, H.-P.DKFZ* ; Becker, N. (Last author)DKFZ* ; Albers, P. (Last author)DKFZ*

2024
Elsevier Science Amsterdam [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/j.eururo.2024.04.030

Abstract: Risk-adjusted screening for prostate cancer (PCa) aims to reduce harms by less frequent retesting, especially in men at a low risk of PCa. Definitions of low risk are based mainly on studies in men starting screening at age 55-60 yr.To identify men at age 45 yr with a low risk of PCa.A population-based, risk-adjusted PCa screening trial was conducted in Germany using baseline prostate-specific antigen (PSA) starting in young men (PROBASE).PSA measurements starting at the age of 45 yr.The incidence of PCa within 5 yr was assessed in men with screen-negative baseline PSA <1.5 ng/ml compared with those with PSA 1.5-≤3.0 ng/ml.Of 23301 men who received a first PSA test at age 45 yr, 0.79% had a screen-positive PSA value of ≥3 ng/ml. Among the 89% of men who had a screen-negative baseline PSA value of <1.5 ng/ml, only 0.45% received a positive PSA test ≥3 ng/ml upon retesting after 5 yr. By contrast, for those with a screen-negative baseline PSA value of 1.5-3 ng/ml, 13% surpassed 3 ng/ml upon biennial testing within the next 4 yr. The incidence of PCa in subsequent screening rounds increased with increasing baseline PSA levels, from 0.13 per 1000 person-years for men with initial PSA level of <1.5 ng/ml to 8.0 per 1000 person-years for those with PSA levels of 1.5-3.0 ng/ml. A limitation is a follow-up time of only 5 yr, so far.Men with baseline PSA <1.5 ng/ml at age 45 yr are at a very low risk of PCa over the next 5 yr.The PROBASE study showed that men with baseline prostate-specific antigen (PSA) <1.5 ng/ml at age 45 yr have a very low prostate cancer detection rate over 5 yr and do not need PSA retesting during this time.

Keyword(s): Low risk ; Prostate cancer ; Prostate-specific antigen ; Screening

Note: #EA:C130#LA:C130# / 2024 Dec;86(6):493-500

---

Contributing Institute(s):

1. Personalisierte Früherkennung des Prostatakarzinoms (C130)
2. C020 Epidemiologie von Krebs (C020)
3. E050 KKE Strahlentherapie (E050)
4. C060 Biostatistik (C060)
5. DKTK Koordinierungsstelle Essen/Düsseldorf (ED01)
6. E010 Radiologie (E010)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2024

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 20 ; JCR ; National-Konsortium ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---